A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating resectable NSCLC. This study has multiple primary endpoints.
Checked against the public recordLast updated Jan 6, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Bristol-Myers Squibb
- Interventions being studied
- Biological: Nivolumab; Drug: Cisplatin; Drug: Vinorelbine; Drug: Gemcitabine; Drug: Docetaxel; Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Ipilimumab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Early stage IB-IIIA, operable non-small cell lung cancer, confirmed in tissue * Lung function capacity capable of tolerating the proposed lung surgery * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 * Available tissue of primary lung tumor Exclusion Criteria: * Presence of locally advanced, inoperable or metastatic disease * Participants with active, known or suspected autoimmune disease * Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion/exclusion criteria apply
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Local Institution - 0121Glendale, Arizona
- Local Institution - 0081Los Angeles, California
- Local Institution - 0025Denver, Colorado
- Local Institution - 0007Plainville, Connecticut
- Local Institution - 0173Hollywood, Florida
- Local Institution - 0136Miami, Florida
- Local Institution - 0054Orlando, Florida
- Orlando Health, Inc.Orlando, Florida
- Indian River Medical CenterVero Beach, Florida
- Northwest Georgia Oncology Center, P.C.Marietta, Georgia
- Local Institution - 0015Chicago, Illinois
- Local Institution - 0002Chicago, Illinois
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 6, 2026. Always confirm current availability with the study team.